Sanofi, Teva Partner To Deliver Bowel Disease Treatment

Sanofi and Teva Pharmaceuticals, a US division of Teva Pharmaceutical Industries Ltd., announce a partnership to co-develop and co-commercialize TEV'574, an inflammatory bowel disease treatment drug currently undergoing phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease. Paul Hudson, chief executive officer, Sanofi, said: “Anti-TL1As are a promising class of therapies, and we believe that TEV’574 could emerge as a best-in-class option for people living with serious gastrointestinal diseases.

This collaboration strengthens our commitment to advancing innovative treatment options for inflammatory conditions with a high unmet need and bolsters our goal to be an industry leader in immunology.” Richard Francis, president and chief executive officer, Teva, said: “This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy. This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honoured to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with our capabilities to optimize development and global launches.”

The new partnership agreement stipulates that Teva would receive an upfront payment of €469 million ($500 million) as well as development and launch milestone payments totaling up to €940 million ($1 billion). Sanofi will oversee the creation of the phase 3 program while each firm will equally split the expenses of global development as well as net revenues and losses in the key markets.